Axoltis Pharma Raises €18M in Series A Funding led by Norfoalk to develop NX210c, aimed at treating ALS.
Amount Raised
€18 Million
Round Type
Series A
LyonBiotechnologyHealth CareTherapeuticsPharmaceuticalInvestors
Description
Axoltis Pharma, a Clermont-Ferrand-based biotech company, raised €18M in Series A funding. The funds will support the development of NX210c, its lead drug candidate currently in phase 2 clinical trials for ALS. The round was led by Norfoalk with participation from several investors, including business angels and the CEO. Axoltis aims to address neurodegenerative diseases with this new therapeutic solution.
Quick answer
Axoltis Pharma raised €18 Million in a Series A round, dated December 2, 2025. Investors: FaDièse 3, Fonds Régional Avenir Industrie Auvergne Rhône Alpes, Ui Investment, Simba Santé 2, Business Angels and Norfoalk. Axoltis Pharma is based in Lyon, Auvergne Rhône Alpes, France.
- How much did Axoltis Pharma raise?
- Axoltis Pharma raised €18 Million in a Series A round on December 2, 2025.
- Who invested in Axoltis Pharma?
- FaDièse 3, Fonds Régional Avenir Industrie Auvergne Rhône Alpes, Ui Investment, Simba Santé 2, Business Angels and Norfoalk are named as investors in this round.
- What does Axoltis Pharma do?
- Axoltis Pharma is a biotech company based in Clermont-Ferrand, France, dedicated to developing therapeutic solutions for neurodegenerative diseases.
- Where is Axoltis Pharma based and how big is it?
- Axoltis Pharma is based in Lyon, Auvergne Rhône Alpes, France. Fundz records about 15 employees.
- Who are the decision-makers at Axoltis Pharma?
- Fundz holds 1 contact at Axoltis Pharma, including the Chief Executive Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Pharmaceutical around the same time
Companies in the same sectors as Axoltis Pharma that raised within 45 days of this round, from Fundz verified event records.
- Os Therapies raised $3.5M on January 14, 2026.
- Parabilis Medicines raised $305M (Series F) on January 8, 2026.
- Navega Therapeutics raised $1.3M (Seed) on January 2, 2026.
- CASI Pharmaceuticals raised $5M on December 27, 2025.
- LeonaBio, Inc. raised $90M (Funding Round) on December 18, 2025.
- Citius Oncology raised $18M (Funding Round) on December 9, 2025.
Who to call at Axoltis Pharma, and when
A new round usually means Axoltis Pharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Axoltis Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Axoltis Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Axoltis Pharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Axoltis Pharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAxoltis Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.